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Acute myocardial infarction (AMI) and the heart failure (HF) that often results are among the 
leading causes of death and disability in the world. As such, novel strategies are required to 
protect the heart against the detrimental effects of acute ischemia/reperfusion injury (IRI), in 
order to reduce myocardial infarct (MI) size and prevent the onset of HF. The endogenous 
cardioprotective strategy of remote ischemic conditioning (RIC), in which cycles of brief 
ischemia and reperfusion are applied to a tissue or organ away from the heart, has been 
reported in experimental studies to reduce MI size in animal models of acute IRI. In the clinical 
setting, RIC can be induced by simply inflating and deflating a cuff placed on the upper arm 
or thigh to induce brief cycles of ischemia and reperfusion, a strategy which has been shown 
to reduce MI size in ST-segment elevation myocardial infarction (STEMI) patients undergoing 
primary percutaneous coronary intervention (PPCI). The results of the ongoing 
CONDI2/ERIC-PPCI trial are eagerly awaited, and will provide definitive answers with regards 
to the cardioprotective effect and clinical outcome benefits of RIC in STEMI.      
 
Introduction and background 
Ischemic heart disease is the leading cause of morbidity and mortality in the world. This 
reflects the increased prevalence of cardiovascular risk factors including cigarette smoking, 
diabetes, hypertension and hypercholesterolemia. These conditions also predispose patients 
to peripheral vascular disease, cerebrovascular disease and, renal disease, adding to disease 
complexity of the cardiovascular patient.  
Up to 25% of ST segment elevation myocardial infarcts (STEMI) are fatal (Laurie J. Lambert, 
James M. Brophy, Normand Racine, Stéphane Rinfret, Philippe L. L’Allier, Kevin A. Brown, 
Lucy J. Boothroyd, Dave Ross, Eli Segal, 2016). Survivors of the acute coronary thrombotic 
occlusion depend on timely revascularization with thrombolysis or primary percutaneous 
5 
 
coronary intervention (PPCI) to abate infarction-induced lethal arrhythmias/cardiac arrest in 
the short term. In the long term, reduced ischemic time leads to smaller infarct size. However, 
despite timely PPCI or thrombolytic therapy, there remains significant morbidity and mortality 
following STEMI. 
The ischemic insult to the myocardium is two-fold; (1) at the time of coronary occlusion; and 
(2) at the time of reperfusion secondary to reperfusion injury. Reperfusion injury can be 
responsible for up to 50% of final infarct size (Hausenloy DJ, 2013). Pump failure secondary 
to non-viable infarcted myocardium is one of the long-term sequelae of STEMI. The ensuing 
heart failure syndrome involves deleterious activation of the renin-angiotensin-aldosterone 
system and peripheral vasoconstriction, leading to sodium and water retention (with worsening 
heart failure) and left ventricular remodeling (hypertrophy, dilation and impaired cardiac 
function) in a patient already burdened with multiple morbidities as outlined. 
To reduce the risk of short and long term complications of infarction, sophisticated and efficient 
systems are in place in many countries for prompt recognition and treatment of STEMI through 
thrombolysis or PPCI. Strategies employed have included ambulance initiation of thrombolysis 
and the development of designated centers providing direct PPCI services to respective 
catchment areas, bypassing the emergency department, with reduction in “pain-to-balloon” 
and “pain-to-thrombolysis” time. However, despite these measures, morbidity and mortality 
following PPCI or thrombolytic therapy remain significant. 
Attenuating myocardial reperfusion injury, the cardiomyocyte death which occurs on 
reperfusing ischemic myocardium, is a potential therapeutic target for reducing infarct 
complications such as cardiac death and re-hospitalization for heart failure (HHF). Accessible 
and effective clinical interventions are required to address reperfusion injury and reduce 
associated complications. In this regard, remote ischemic conditioning (RIC) has been shown 
to reduce perioperative myocardial injury in patients undergoing coronary artery bypass graft 
(CABG) surgery in small studies, but the beneficial effects of RIC have not been reproduced 
in large clinical outcome studies. In contrast, RIC remains a promising cardioprotective 
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strategy in STEMI patients undergoing PPCI. In this article, we review the therapeutic potential 
for RIC as a cardioprotective strategy for reducing MI size and improving clinical outcomes 
post-PPCI.  
 
Remote ischemic conditioning – cardioprotection from a distance 
Przyklenk et al. (Przyklenk K, Bauer B, Ovize M, Kloner RA, 1993) were the first to describe 
the cardioprotective phenomenon of remote ischemic preconditioning in 1993, where 4x5 
minute cycles of occlusion and reflow to the circumflex coronary artery reduced MI size in a 
canine heart induced by 45 minute occlusion and 3 hrs reperfusion of the left anterior 
descending artery (Przyklenk K, Bauer B, Ovize M, Kloner RA, 1993). This study suggested 
that cardioprotection could be transferred from one coronary artery territory to another through 
ischemic preconditioning (Przyklenk K, Bauer B, Ovize M, Kloner RA, 1993). This concept was 
then extended to the remote organ, the kidney, by McClanahan et al., who showed that 10 
minute occlusion and reflow in the renal artery could reduce MI size induced by 30 minute 
ligation and 3 hrs reperfusion of the left main coronary artery (McClanahan TB, Nao BS, Wolke 
LJ, Martin BJ and KP, 1993). Oxman et al. demonstrated that RIC could be applied non-
invasively, using a tourniquet applied to the hindlimb (Oxman T, Arad M, Klein R, Avazov N, 
1997), a key finding in the translation of RIC into the clinical setting. 
Two key properties of RIC have facilitated its translation into the clinical setting (see Figure 1 
for time-line of translation of RIC from experimental to clinical studies):  
(1) Feasibility: In an experimental animal MI model, the RIC stimulus could be applied to the 
hind limb to protect the heart against acute IRI (Oxman T, Arad M, Klein R, Avazov N, 1997) 
(Birnbaum Y, Hale SL, 1997). The RIC stimulus can be delivered non-invasively in human 
volunteers by inflating a blood pressure cuff on the upper arm to induce cycles of brief 
ischemia-reperfusion (Kharbanda RK, Mortensen UM, 2002). Hence, most clinical studies 




(2) Flexibility: In ischemic preconditioning (IPC), the protective stimulus has to be applied 
prior to ischemia and in ischemic postconditioning (IPost), at the onset of reperfusion to the 
heart directly. RIC can be applied at any time (before, after the onset of, or at the end of 
ischemia) to a remote organ or tissue. 
 
Mechanisms underlying RIC cardioprotection 
The actual mechanistic pathways underlying RIC cardioprotection is not known but it has been 
established that a neurohormonal pathway links the distal organ or tissue to the heart. The 
pathway linking the remote organ or tissue to the heart is believed to involve the release of 
local autacoids stimulating the sensory afferent neural pathway in the remote organ or tissue 
resulting in the production of a circulating transferrable blood-borne factor(s) conferring 
cardioprotection. Current evidence suggests the factor is thermolabile and hydrophobic, and 
is between 3.5 and 30 kDa. There is likely a complex interaction of signaling pathways in 
response to RIC, linking to the regulation of various cellular functions, including the acute 
phase response, immune response, hemostasis and lipid transport (V. Sivaraman and 
Hausenloy, 2015). 
A number of candidate molecules have been suggested to be the blood‐borne cardioprotective 
mediator of RIC including opioid (Dickson EW, Blehar DJ, Carraway RE, Heard SO and K, 
2001), adenosine (Leung CH, Wang L, 2014), bradykinin (Schoemaker RG, 2000), 
erythropoietin, calcitonin gene related peptide, stromal derived factor 1‐alpha (SDF1‐α) 
(Davidson SM, Selvaraj P, 2013), hypoxia inducible factor 1‐alpha (HIF1‐α) and nanoparticles 
produced by cells called exosomes (Giricz Z, Varga ZV, 2014). Adenosine, bradykinin and 
calcitonin gene-related peptide (CGRP) may activate afferent neural pathways within the 
remote preconditioned organ to confer cardioprotection (Hausenloy DJ and Yellon DM, 2008). 
Activation of protein kinase C appears to be an important step in humoral cardioprotection in 
rats (Serejo FC, Rodrigues LF Jr, da Silva Tavares KC and AC, 2007).  
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Naloxone appears to block the cardioprotective effect of RIC in rats (Patel HH, Moore J, Hsu 
AK, 2002). Endogenous opioids generated by remote preconditioning may be a humoral factor 
conferring cardioprotection (Patel HH, Moore J, Hsu AK, 2002). It has been proposed that 
endocannabinoids generated by intestinal ischemia may activate CB2 endocannabinoid 
receptors on the myocardium in cardioprotection (Hajrasouliha AR, Tavakoli S, Ghasemi M 
and et al Sadeghipour H, 2008). Remote ischemic preconditioning (RIPC) appears to suppress 
the inflammatory response and activate an anti-inflammatory, anti-apoptotic gene transcription 
profile (Konstantinov IE, Arab S, Kharbanda RK, Li J, Cheung MM and Al, 2004) (Konstantinov 
IE, Arab S, Li J, Coles JG, Boscarino C, 2005) (Peralta C, Fernandez L, Panes J, Prats N, 
Sans M, 2001). Further investigation of relevance to cardioprotection is required. KATP 
channels of the myocardial sarcolemma and mitochondria have been implicated in IPC 
cardioprotection (Yellon DM, 2003). Ligand receptor binding at the cell surface activates signal 
transduction pathways which open mitochondrial KATP channels. The generation of 
mitochondrial reactive oxygen species then mediates cardioprotection by either activating pro-
survival kinases (Yellon DM, 2003) or inhibiting mitochondrial permeability transition pore 
(mPTP) opening (Costa AD, Jakob R, Costa CL, Andrukhiv K, West IC, 2006). ĸ-opioid agonist 
induces mPTP opening (Zhang SZ, Wang NF, Xu J, Gao Q, Lin GH, 2006). Remote rat limb 
preconditioning can mediate cardioprotection through ĸ-opioid receptor blockade (Zhang SZ, 
Wang NF, Xu J, Gao Q, Lin GH, 2006). 8-sulphophenyltheophylline (8-SPT), a non-specific 
adenosine receptor antagonist, could block the cardioprotective effect of RIC performed on 
the rabbit kidney if administered prior to preconditioning (Pell TJ, Baxter GF, Yellon DM, 1998) 
and also after preconditioning (Takaoka A, Nakae I, Mitsunami K, Yabe T, Morikawa S, 1999). 
Elevated adenosine levels in carotid artery blood of rabbits subjected to preconditioning 
suggests that myocardial adenosine receptor binding is a key step in the mechanism of 
preconditioning (Takaoka A, Nakae I, Mitsunami K, Yabe T, Morikawa S, 1999). Free radical 
scavenger was able to block the cardioprotective effect of RIC (Weinbrenner C, Schulze F, 
Sarvary L, 2004), implicating signaling reactive oxygen species as a mediator of RIC 
cardioprotection. Transection of the femoral nerve before application of the RIC stimulus 
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blocked cardioprotection (Lim SY, Yellon DM, 2010) (Steensrud T, Li J, 2010). Ding et al. 
noted that brief renal artery occlusion was associated with increased afferent renal nerve 
activity, and nerve transection also blocked RIC‐induced cardioprotection (Ding YF, Zhang 
MM, 2001). Direct stimulation of the sensory nerve of the remote organ or tissue has been 
reported to reproduce the cardioprotective effect of RIC (Dong JH, Liu YX, Zhao J, Ma HJ, 
Guo SM, 2004) (Merlocco AC, Redington KL, 2014) (Redington KL, Disenhouse T, 2013). 
Stimulation of cutaneous sensory nerves, using either topical application of capsaicin 
(Redington KL, Disenhouse T, 2012) or surgical skin incision (Ren X, Wang Y, 2004) (Gross 
GJ, Baker JE, Moore J, Falck JR, 2011), has been reported to mimic RIC cardioprotection. 
 
Clinical application of remote ischemic conditioning 
Cardiac bypass surgery as a clinical setting for cardioprotection 
The first clinical setting for RIC to be tested in was cardiac bypass surgery, in which the heart 
is subjected to a global ischemic insult when put onto cardiopulmonary bypass, followed by 
global reperfusion injury (acute IRI) when taken off cardiopulmonary bypass (Venugopal V, 
Ludman A, 2009). Direct handling of the heart, coronary embolization, and the inflammatory 
response to cardiopulmonary bypass can all contribute to perioperative myocardial injury 
(PMI)which can be quantified by measuring serum cardiac enzymes (Creatine Kinase MB 
isoenzyme, Troponin T and I) (Croal BL, Hillis GS, 2006) (Wang TK, Stewart RA, 2013), and 
can be detected as late gadolinium enhancement (LGE) on cardiovascular magnetic 
resonance imaging (CMR) (Selvanayagam JB, Porto I, 2005). The presence of PMI has been 
associated with worse clinical outcomes post-cardiac surgery (Croal BL, Hillis GS, 2006) 
(Wang TK, Stewart RA, 2013).  
The first attempt to clinically apply RIC involved only eight patients, in a study in which 
remote limb preconditioning failed to affect CK-MB in elective patients undergoing cardiac 
surgery (Gunaydin B, Cakici I, Soncul H, Kalaycioglu S, Cevik C, 2000). This study was 
underpowered; CK-MB was measured 5 minutes after declamping the aorta; cuff inflation to 
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300 mmHg was used; and an inadequate RIPC protocol was used with two cycles of 3 minute 
upper limb ischemia followed by 2 minute reperfusion (Gunaydin B, Cakici I, Soncul H, 
Kalaycioglu S, Cevik C, 2000).  
Cheung et al. were the first to successfully apply RIPC clinically (Cheung MM, Kharbanda RK, 
Konstantinov IE, Shimizu M, Frndova H, 2006). They reported that an RIPC protocol using 
four 5 minute cycles of lower limb ischemia was able to reduce myocardial injury, improve 
airway resistance, and decrease inotrope score in 17 children undergoing congenital cardiac 
surgery (Cheung MM, Kharbanda RK, Konstantinov IE, Shimizu M, Frndova H, 2006). 
Hausenloy et al (Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, Barnard M and Al, 
2007) demonstrated that RIPC, using three-5 min cycles of upper limb ischemia, was able to 
reduce myocardial injury (43% reduction in serum troponin-T released over 72 hours) in adult 
patients undergoing elective coronary artery bypass grafting surgery. RIPC using limb 
ischemia has also been reported to be cardioprotective in the setting of repair of abdominal 
aortic aneurysm (AAA) elective surgery (Ali ZA, Callaghan CJ, Lim E, Ali AA, Nouraei SA, 
2007). Ali et al demonstrated that invasive lower limb ischemia using two 10 minute episodes 
of iliac artery occlusion was able to reduce myocardial injury (27% reduction in serum troponin-
I released over the perioperative period) and preserve renal function during elective AAA 
surgical repair (Ali ZA, Callaghan CJ, Lim E, Ali AA, Nouraei SA, 2007). 
The results of several recent meta-analyses have confirmed the cardioprotective 
effects of RIC cardiac bypass surgery in attenuating perioperative myocardial injury (Haji Mohd 
Yasin NA, Herbison P, 2014) (Healy DA, Khan WA, 2014).  There have, however, been several 
neutral studies (Karuppasamy P, Chaubey S, 2011) (Young PJ, Dalley P, 2012) (Rahman IA, 
Mascaro JG, 2010) including at least one very large study (McCrindle BW, Clarizia NA, 2014).  
RIPHeart study (Meybohm et al., 2015): 1403 adults undergoing elective cardiac surgery with 
cardiopulmonary bypass under general anesthesia with intravenous propofol were 
randomized to upper-limb RIPC or sham intervention. No significant differences between the 
RIPC group and the sham-RIPC group were seen in the level of troponin, the duration of 
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mechanical ventilation, the length of stay in the intensive care unit, the length of hospital stay, 
incidence of new onset atrial fibrillation, and the incidence of postoperative delirium. 
 
ERICCA study (Hausenloy et al., 2015a): 1612 patients undergoing elective on-pump CABG 
with or without valve surgery were randomly assigned to RIPC or sham conditioning. There 
was no standardization of anesthetic management and perioperative care. The combined 
primary end point was death from cardiovascular causes, nonfatal myocardial infarction, need 
for coronary revascularization, or stroke at 12 months from randomization. RIPC was not 
shown to improve clinical outcomes in patients undergoing elective on-pump CABG with or 
without valve surgery. 
The reasons for this discrepancy may relate to: patient/clinical factors (CABG vs valve 
surgery, stable vs unstable patients); timing of the limb RIC protocol (before vs after surgical 
incision); blinding to the RIC protocol (proper vs limited blinding); the intensity of the RIC 
protocol (3 vs 4 cycles of limb RIC and inflation of cuff to 200mmHg vs 15mmHg above systolic 
blood pressure); and the presence of confounding factors. 
 
Propofol and volatile anaesthetic agents – potential confounding factors 
Attenuation of RIC has been noted when propofol anaesthesia has been used (Bautin et al., 
2014), and the use of propofol, rather than volatile anaesthesia, appears to be a common 
factor in studies that failed to protect with RIC in CABG (Heusch, 2013; Zangrillo et al., 2015). 
The American College of Cardiology Foundation and the American Heart Association Task 
Force on Practice Guidelines have recommended the use of volatile anaesthetics in surgical 
patients with increased cardiovascular risk (Fleisher et al., 2008). Whether RIC provides 
additional cardioprotection to the use of volatile anaesthetic in patients undergoing cardiac 
surgery is uncertain with clinical studies showing mixed results.  
 
Diabetes may attenuate RIC cardioprotection through neurohumoral pathways  
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Single-dose RIC does not appear to offer much cardioprotection in diabetic patients (Xu et al., 
2014; Baranyai et al., 2015; Epps and Smart, 2016; Lejay et al., 2016) and the mechanisms 
of which are not well understood. About 60% to 70% of people with diabetes mellitus will 
eventually develop the complication of diabetic peripheral neuropathy (Boulton et al., 2005). 
In many of these patients, sensory C fibers mediate the cardioprotective effect of RIC, are 
damaged (Green et al., 2010) and this may be an important contributor to the attenuation of 
RIC cardioprotection (Saxena et al., 2010; Jensen et al., 2012). It may be necessary to exclude 
patients with diabetic neuropathy or sensory neuropathy from future clinical trials in RIC. In 
addition, diabetes affects the intracellular signaling pathways that are crucial for endogenous 
cardioprotection. These include: PI3K/Akt/glycogen synthase kinase 3 beta (PI3K/Akt/GSK3-
β) signaling pathway, phosphorylation of ERK1/2 (extracellular signal-regulated protein 
kinases 1 and 2), generation and release of nitric oxide, ATP-sensitive potassium channels, 
and oxidative stress generation (Chen et al., 2012; Baumgardt et al., 2016; Wang and Zhao, 
2016). This may further contribute to the attenuation of RIC cardioprotection. 
 
PPCI as a clinical setting for RIC cardioprotection  
Timely myocardial reperfusion by PPCI is the most effective therapy for limiting MI size and 
preserving LV systolic function in patients presenting with STEMI. Restoration of coronary 
blood flow in the occluded artery results in myocardial reperfusion injury which may be  
amenable to cardioprotection by IPost and RIC (Bulluck and Hausenloy, 2015).  
In several proof-of-concept studies, limb RIC appeared to be effective when administered by 
paramedics in the ambulance (Botker HE, Kharbanda R, 2010a), on hospital arrival prior to 
PPCI (Rentoukas I, Giannopoulos G, 2010a) (White SK, Frohlich GM, 2014), and even at the 
onset of reperfusion with PPCI (Crimi G, Pica S, 2013). Please see Table 1 for summary of 
major clinical studies in STEMI patients. 
Bøtker et al. (Botker HE, Kharbanda R, 2010b) in the CONDI trial were the first group to test 
the effect of RIC in patients with STEMI. The study involved 142 STEMI patients with the 
primary endpoint being myocardial salvage index at 30 days post PPCI, measured by 
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myocardial perfusion imaging as the proportion of the area at risk salvaged by treatment. They 
found an increase in myocardial salvage index at 30 days with no difference in MI size 
measured by SPECT or peak troponin. Reduced MI size was found however in LAD STEMI.  
Crimi et al. (Crimi et al., 2013) then assessed the effect of RIC on 100 anterior STEMI patients 
and found a 20% reduction in 72 hour AUC CK–MB and a 21% reduction in myocardial 
oedema by MRI. This was the first study to show the effect of RIC given at onset of reperfusion, 
and the first to report the effect of RIC on enzymatic MI size and myocardial oedema. 
It has been observed that the beneficial effect of RIPC can be inhibited by the opioid receptor 
blocker naloxone (Patel HH, Moore J, Hsu AK, 2002). Rentoukas et al (Rentoukas I, 
Giannopoulos G, 2010b) sought to assess the enhancement of the cardioprotective effect of 
RIC by opioids by having 3 arms in their study comprising of RIC only group, RIC and morphine 
group and control group. In paired comparisons between groups, the RIC and morphine group 
performed better than the control group in terms of both ST-segment reduction and peak 
troponin I, whereas the differences in outcomes between the RIC only group and the control 
group did not reach statistical significance.   
Munk et al. (Munk et al., 2010) analysed the effect of RIC in relation to the size of the 
myocardial area at risk (AAR), infarct location, and target vessel patency in a study involving 
242 STEMI patients. Ejection fraction, LV volumes (2D and 3D echocardiography and 
myocardial perfusion imaging), and speckle-tracking global longitudinal strain were compared 
between treatment groups. Although no significant overall effect was observed, RIC seemed 
to result in modest improvement in LV function in high-risk patients prone to develop large 
myocardial infarcts. 
Sloth et al. (Sloth et al., 2014) performed a study involving 251 STEMI patients. The RIC 
intervention was 4 × 5 min inflations/deflations of cuff on upper arm in the ambulance before 
PPCI without sham control. This showed a 51% reduction in all-cause mortality, nonfatal MI, 
TIA or stroke, HHF at 3.8 years and was the first study to test effect of RIC on long-term 
outcomes after PPCI as a secondary end point. 
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Prunier et al. (Prunier et al., 2014) had a study arm involving PPCI combined with RIC and 
IPost which consisted of four cycles of 1-min inflation and 1-min deflation of the angioplasty 
balloon in their study consisting of 55 STEMI patients. RIC immediately prior to PPCI was 
shown to reduce infarct size in STEMI patients, yet combining this therapy with an IPost 
strategy did not lead to further decrease in infarct size. 
In the study by White et al in 2015 (White et al., 2015), 197 patients with ST-segment elevation 
myocardial infarction with TIMI (Thrombolysis In Myocardial Infarction) flow grade 0 were 
randomly assigned to receive RIC (four 5-min cycles of upper arm cuff inflation/deflation) or 
control (uninflated cuff placed on upper arm for 40 min) protocols prior to PPCI. This study 
aimed to determine whether RIC performed (PPCI) could reduce myocardial infarct (MI) size, 
assessed by cardiac MRI, in patients presenting with ST-segment elevation myocardial 
infarction. The primary study endpoint was MI size assessed by cardiac MRI in 83 subjects on 
days 3 to 6 after admission. RIC was found to reduce MI size by 27%, when compared with 
the MI size of control subjects. At 24 hours, high-sensitivity troponin T was lower with RIC. 
RIC also reduced the extent of myocardial oedema measured by T2-mapping CMR and 
lowered mean T2 values. This precluded the use of CMR oedema imaging to accurately 
estimate the area at risk. When using coronary angiography jeopardy scores to estimate the 
area at risk, RIC was found to significantly improve the myocardial salvage index. This study 
demonstrated that RIC, performed in patients with STEMI treated by PPCI, reduced MI size, 
increased myocardial salvage, and reduced myocardial oedema when performed prior to 
PPCI.  
Yellon et al. (Yellon et al., 2015) performed the ERIC-LYSIS study, which is the only study to 
test effect of RIC in thrombolysed patients with STEMI. 519 STEMI patients were randomised 
to 4 × 5 min inflations/deflations of cuff on upper arm at the hospital before thrombolysis or 
sham control with deflated cuff application. There was a 17% reduction in enzymatic MI size 
(CK–MB and troponin T) in the RIC group.   
In the LIPSIA CONDITIONING study by Eitel et al. (Eitel et al., 2015) involving 333 STEMI 
patients, improved myocardial salvage was seen when IPost was combined with RIC. Neither 
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IPost alone nor RIC + IPost reduced myocardial oedema. No difference in MI size, MVO, or 
6-month clinical end points (death, re-infarction, and heart failure at 6 months) were seen.  
Renal outcomes were assessed by Yamanaka et al. (Yamanaka et al., 2015) in a 94-STEMI 
patient study with the primary endpoint being incidence of contrast induced-AKI after 
administration of contrast medium. The odds ratio of CI-AKI in patients who received RIPC 
was 0.18 (95% confidence interval: 0.05-0.64; p=0.008). Lower incidence of ventricular 
arrhythmia was also noted in the RIC group within 24 hours of RIC.  
The study by Verouhis et al. (Verouhis et al., 2016) has been the only neutral study of RIC in 
STEMI. The use of a non-standard RIC protocol comprising of variable numbers of RIC cycles 
(as many as 7-9) were used and may have contributed to the neutral results. The primary 
endpoint of the study was infarct size expressed as myocardial salvage index determined by 
CMR on days 4-7 after PCI. There was no significant difference in myocardial salvage index 
between the RIPerC and PCI group. 
Liu et al. (Liu et al., 2016) performed the first study to assess the effect of RIC in STEMI 
patients through the use of CMR to detect early microvascular obstruction. The primary study 
end point was early microvascular obstruction measured by CMR. There was a significant 
decrease in early microvascular obstruction as assessed by CMR in the RIC group.  
Most recently, Gaspar et al found that RIC administered prior to PPCI improved clinical 
outcomes following STEMI with reduced rates of HHF (Gaspar et al., 2018). This is the first 
prospectively designed study to investigate the effect of RIC on clinical outcomes following 
STEMI as primary endpoint. RIC was shown to be beneficial in a combined clinical endpoint 
of cardiac mortality and hospitalisation for HF. Improved EF recovery was also documented 
in patients with impaired LV function. In-hospital heart failure risk and need for diuretics, 
inotropes and/or intra-aortic balloon pump were reduced in RIC group.   
In a large European multicentre study, the CONDI2/ERIC-PPCI trial (ClinicalTrials.gov 
Identifier: NCT02342522) is investigating, whether RIC initiated prior to PPCI can reduce the 
rates of cardiac death and hospitalisation for heart failure at 12 months as the primary 
endpoint. It is a prospective, randomized-controlled trial of 5200 STEMI patients undergoing 
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PPCI. Patients have been randomized to either RIC or sham control. Secondary endpoints 
include: (i) Rates of cardiac death and heart failure hospitalization at 30 days, (ii) Rates of all-
cause death, coronary revascularization, re-infarction, stroke at 30 days and at 12 months, (iii) 
TIMI flow post-PPCI, (iv) ST-segment resolution on ECG taken at 90 minutes, (v) Enzymatic 
MI size as assessed from a 48 h area-under-the-curve (AUC) high-sensitive Troponin-T 
(hsTrop-T) using blood samples collected at time 0, 6, 12, 24, and 48 hours in a sub-study, 
(vi) MI size as measured by cardiac magnetic resonance (CMR) scan performed at 6 months 
in a sub-study. It is well established that RIC can reduce MI size in STEMI patients who have 
received PPCI. It is not known whether this beneficial effect translates to improved clinical 
outcomes. The results of the CONDI2/ERIC-PPCI study, which will be available in Summer 
2019, will establish whether limb RIC, as a non-invasive low-cost intervention, can improve 
long-term clinical outcomes in STEMI patients treated with PPCI. 
 
Challenges and future directions 
Several post-hoc analyses of RIC in STEMI studies have shed further insights. In the post-
hoc analysis by Pryds et al. (Pryds et al., 2016a) assessing the influence of pre-infarction 
angina and coronary collateral blood flow (CCBF) on the effectiveness of RIC in STEMI 
patients, pre-infarction angina was found not to modify RIC efficacy in STEMI patients 
undergoing PPCI. CCBF to the infarct-related artery seemed to affect the cardioprotective 
efficacy of RIC, with mean myocardial salvage index (MSI) being increased in patients with 
CCBF versus without CCBF in the RIC with PPCI group. Pryds et al. (Pryds et al., 2016b) also 
found, in a separate post-hoc analysis, that RIC as adjunct to PPCI attenuated the detrimental 
effect of healthcare system delay on myocardial salvage in patients with STEMI. In patients 
with healthcare system delay >120 min, RIC with PPCI increased median MSI compared with 
PPCI alone, suggesting that the cardioprotective effect of RIC increases with the duration of 
ischemia. Sloth et al. (Sloth et al., 2015) found no significant difference in the effectiveness of 
RIC in subgroups of cardiovascular risk factors, lipid and glucose levels, and medication use 
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in their post-hoc analysis. Sloth et al. (Sloth et al., 2016) also performed a post-hoc analysis 
addressing the issue of cost-effectiveness of RIC in STEMI patients. They found that after 4 
years of follow-up, mean cumulative cardiovascular medical care costs were lower in the RIC 
group than in the control group, while mean major adverse cardiac and cerebrovascular event-
free survival time was 0.30 years higher in the RIC than in the control group. These results 
suggest that RIC in STEMI appears to be a cost-effective treatment strategy in patients with 
STEMI. 
 
Daily RIC following STEMI  
Chronic renal failure patients undergoing haemodialysis are subjected to repeated episodes 
of acute myocardial ischemia resulting in myocardial stunning and chronic LV systolic 
impairment (Crowley LE, 2013). Limb RIC has been reported to attenuate ST-segment 
depression and prevent myocardial stunning in these patients (Crowley LE, 2013).  
One experimental study has demonstrated that performing limb RIC daily for a period of 28 
days prevented adverse post-MI LV remodeling in the rat heart (Wei M, Xin P, 2011). This 
approach has been tested in the clinical setting in two studies.  
DREAM (Vanezis et al., 2018): This trial assessed the role of daily RIC in improving left 
ventricular ejection fraction (LVEF) recovery in patients with reduced LVEF (<45%) after 
STEMI treated with PPCI. Patients were recruited from four UK hospitals and randomised to 
receive either 4 weeks of daily RIC or sham conditioning commencing on day 3 post P-PCI. 
The primary endpoint was the improvement in LVEF over 4 months assessed by cardiac MRI. 
73 patients (38 cases, 35 controls) completed the study. There was no difference in the 
improvement in LVEF over 4 months between the treatment and control groups. No 
differences were seen in the secondary outcome measures of changes in infarct size and left 
ventricular end-diastolic and systolic volumes, major adverse cardiac and cerebral events, 
mean Kansas City Cardiomyopathy Questionnaire score and change in N-terminal pro-brain 
natriuretic peptide levels. Daily RIC starting on day 3 and continued for 4 weeks following P-
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PCI for STEMI did not improve LVEF as assessed by CMR after 4 months when compared 
with a matched control group. The failure to begin RIC immediately prior to PPCI may have 
contributed to the neutral results of this study, and in this regard, the ongoing CRIC-RCT trial 
(NCT01817114) which is initiating RIC prior to PPCI and administering RIC daily for one 
month may provide further insights.   
 
Summary and Conclusions 
RIC provides an easily applied and very effective endogenous strategy for reducing MI size 
following acute IRI. Despite extensive studies, the actual mechanistic pathway underlying RIC 
cardioprotection remains unclear - although a neurohormonal pathway is believed to be 
critical, the exact interplay between the neural and hormonal pathway is yet to be determined, 
and the identity of the cardioprotective humoral factors remain unknown. RIC has been 
successfully tested in a number of clinical settings including CABG surgery, elective PCI and 
more recently and most promisingly in STEMI patients undergoing PPCI. The translation of 
RIC into patient benefit has been elusive for CABG surgery patients, and this failure may be 
attributed to insufficient information on the optimum RIC protocol, the effects of co-medications 
of RIC cardioprotection such as propofol anesthesia and use of nitrates, and the presence of 
age and co-morbidities such as diabetes. RIC has most promise for STEMI patients 
undergoing PPCI, and the results of the CONDI2/PPCI study which are due in Summer 2019 
are eagerly awaited, and will provide the definitive answer as to whether RIC can improve 
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Table 1 - Major clinical studies of RIC in STEMI  





RIC protocol  Main outcomes  Notes  
Bøtker et al. (Botker 
HE, Kharbanda R, 
2010b) CONDI 
(2010)   
142  All STEMI 4 × 5 min 
inflations/deflations of cuff 
on upper arm in the 
ambulance before PPCI  
Sham control: none  
 
Primary endpoint: Myocardial salvage 
index at 30 days post PPCI, measured 
by myocardial perfusion imaging as the 
proportion of the area at risk salvaged by 
treatment 
Increase in myocardial salvage index at 
30 days  
No difference in MI size (SPECT or peak 
troponin) 
First study to test effect of RIC in patients with 
STEMI  
Reduced MI size in LAD STEMI  
 
Munk et al. (Munk et 
al., 2010)  
(2010) 
242 All STEMI 4 × 5 min 
inflations/deflations of cuff 
on upper arm in the 
ambulance before PPCI  
Sham control: none  
 
Ejection fraction, LV volumes (2D and 
3D echocardiography and myocardial 
perfusion imaging), and speckle-tracking 
global longitudinal strain were compared 
between treatment groups. 
Although no significant overall effect was 
observed, RIC seemed to result in 
modest improvement in LV function in 
high-risk patients prone to develop large 
myocardial infarcts 
The effect of RIC was analysed in relation to 
the size of the myocardial area at risk (AAR), 
infarct location, and target vessel patency. 





93  All STEMI 3 × 4 min 
inflations/deflations of cuff 
on upper arm at the 
hospital before PPCI  
Sham control: 3 × 5 min 
low-pressure 
inflations/deflations  
Better ST-segment resolution and lower 
peak troponin I  
Additive effects with morphine  
Combined effects of RIC with morphine  
 
Crimi et al. (Crimi et 
al., 2013)  
(2013)   
100  Anterior 
STEMI only 
3 × 5 min 
inflations/deflation of cuff 
on thigh at onset of 
reperfusion  
Sham control: none  
20% reduction in 72 h AUC CK–MB  
21% reduction in myocardial oedema by 
MRI  
 
First study to show effect of RIC given at 
onset of reperfusion, and first to report effect 
of RIC on enzymatic MI size and myocardial 
oedema  
Sloth et al. (Sloth et 
al., 2014)  
251  All STEMI 4 × 5 min 
inflations/deflations of cuff 
on upper arm in the 
ambulance before PPCI  
51% reduction in all-cause mortality, 
nonfatal MI, TIA or stroke, HHF at 3.8 
years  
 
First study to test effect of RIC on long-term 






Sham control: none 
Prunier et al. (Prunier 
et al., 2014) 
(2014) 
55 All STEMI 3 × 5 min 
inflations/deflations of cuff 
on upper arm in before 
PPCI  
Sham control: none 
RIC immediately prior to PPCI was 
shown to reduce infarct size in STEMI 
patients, yet combining this therapy with 
an IPost strategy did not lead to further 
decrease in infarct size. 
Study had arm involving PPCI combined with 
RIC and IPost which consisted of four cycles 
of 1-min inflation and 1-min deflation of the 
angioplasty balloon. 




83  All STEMI 4 × 5 min 
inflations/deflations of cuff 
on upper arm at the 
hospital before PPCI  
Sham control: deflated 
cuff  
27% reduction in MI size by MRI  
19% reduction in myocardial oedema by 
MRI  
 
First study to show effect of RIC given before 
PPCI on MI size and myocardial oedema by 
MRI  
 




519  All STEMI 4 × 5 min 
inflations/deflations of cuff 
on upper arm at the 
hospital before 
thrombolysis  
Sham control: deflated 
cuff  
17% reduction in enzymatic MI size (CK–
MB and troponin T)  
Only study to test effect of RIC in 
thrombolysed patients with STEMI  
 




(2015)    
333  All STEMI 4 × 5 min 
inflations/deflations of cuff 
on upper arm at the 
hospital before PPCI plus 
IPost  
Sham control: none  
 
Increased myocardial salvage with RIC + 
IPost versus control (49 versus 40)  
No difference in MI size, MVO, or 
6-month clinical end points (death, re-
infarction, and heart failure at 6 months)  
 
Improved myocardial salvage when IPost 
combined with RIC  
Neither IPost alone nor RIC + IPost reduce 
myocardial oedema  
 
Yamanaka et al. 
(Yamanaka et al., 
2015) 
(2015) 
94 All STEMI 3 × 5 min 
inflations/deflations of cuff 
on upper arm at the 
hospital before PPCI 
Sham control: Yes 
Primary endpoint: Incidence of contrast 
induced-AKI after administration of 
contrast medium 
Odds ratio of CI-AKI in patients who 
received RIPC was 0.18 (95% 
confidence interval: 0.05-0.64; p=0.008) 
Lower incidence of ventricular arrhythmia was 
noted in the RIC group within 24 hours of RIC 
Verouhis et al. 




5-minute cycles of 
inflation and deflation of a 
blood pressure cuff 
around the left thigh which 
was continued throughout 
the PCI procedure 
Sham control: Yes 
The primary endpoint of the study was 
infarct size expressed as myocardial 
salvage index determined by CMR on 
days 4-7 after PCI. 
There was no significant difference in 
myocardial salvage index between the 
RIPerC and PCI group 
This study has been the only neutral study 
RIC STEMI study. The use of a non-standard 
RIC protocol comprising variable numbers of 
RIC cycles (as many as 7-9) were used and 
may have contributed to the neutral results.  
30 
 
Liu et al. (Liu et al., 
2016)  
(2016) 
119 All STEMI 4 × 5 min inflations to 200 
mmHg /deflations of cuff 
on upper arm in the 
ambulance before PPCI  
Sham control: none 
The primary study end point was early 
microvascular obstruction measured by 
CMR. 
There was a significant decrease in early 
microvascular obstruction as assessed 
by CMR in the RIC group 
This was the first study to assess the effect of 
RIC in STEMI patients through the use of 
CMR to detect early microvascular 
obstruction. 
Gaspar et al. (Gaspar 
et al., 2018)  
(2018) 
448 All STEMI 3 × 5 min 
inflations/deflations of cuff 
on upper arm in before 
PPCI  
Sham control: Yes 
RIC was shown to be beneficial in a 
combined clinical endpoint of cardiac 
mortality and hospitalisation for HF. 
Improved EF recovery was also 
documented in patients with impaired LV 
function. In-hospital heart failure risk and 
need for diuretics, inotropes and/or intra-
aortic balloon pump were reduced in RIC 
group  
First prospectively designed study to 
investigate the effect of RIC on clinical 
outcomes following STEMI as primary 
endpoint.   
CONDI-2/ ERIC-PPCI 
(Hausenloy et al., 
2015b) 
5,400 All STEMI 4 × 5 min 
inflations/deflations of cuff 
on upper arm before PPCI  
Sham control: none or 
simulated  
Ongoing study  
Primary end point of cardiac death and 
HHF at 12 months  
Collaboration between Denmark, Serbia, 
Spain, and the UK  
First study to test effect of RIC on long-term 













Figure 1. This figure shows the time-line of translation of RIC from experimental to clinical 
studies   
 
  
